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Abstract
Background—Oral endocrine therapy (OET) such as Tamoxifen or aromatase inhibitors reduces 
recurrence and mortality for the 75% of breast cancer survivors (BCS) diagnosed with estrogen-
receptor positive breast cancer. Because many BCS decide not take OET as recommended due to 
side effects, understanding BCS's decisional supports and needs is foundational to supporting 
quality OET decision making about whether or not to adhere to OET.
Objective—To examine literature pertaining to OET non-adherence and side effects using the 
Ottawa Decision Support Framework categories of decisional supports and decisional needs as 
these factors potentially influence OET use.
Methods—A systematic literature search was performed in PubMed and CINAHL using 
combined search terms “aromatase inhibitors and adherence” and “tamoxifen and adherence.” 
Studies that did not meet criteria were excluded. Relevant data from 25 publications was extracted 
into tables and reviewed by two authors.
Results—Findings identified: the impact of side effects on OET non-adherence; an absence of 
decisional supports provided to or available for BCS who are experiencing OET side effects; and 
the likelihood of unmet decisional needs related to OET.
Conclusions—Side effects contribute to BCS's decisions to stop OET, yet there has been little 
investigation of the process through which that occurs. This review serves as a call to action for 
providers to provide support to BCS experiencing OET side effects and facing decisions related to 
non-adherence.
Implications for Practice—Findings suggest BCS prescribed OET have unmet decisional 
needs and more decisional supports are needed for BCS experiencing OET side effects.
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Oral endocrine therapy (OET) is standard therapy for estrogen receptor-positive (ER+) 
breast cancer.1 An estimated 75% of women with breast cancer receive a recommendation 
for life-saving OET such as tamoxifen or aromatase inhibitors.1 OET is prescribed for ER+ 
breast cancer to prevent recurrence by blocking certain hormones that fuel cancer growth.
The approach to oral endocrine therapy treatment in BCS with ER+ breast cancer depends 
on whether or not a woman is in menopause. Tamoxifen is prescribed to pre-, peri, or 
postmenopausal women and has been shown to decrease breast cancer recurrence by 41% 
and mortality by 34%.2, 3 Aromatase inhibitors (AI)s, prescribed only for postmenopausal 
women, have been shown to reduce recurrence by 30%-41% and metastasis by 16%-18%, 
with mortality rate reductions similar to tamoxifen. 2, 3 4As a class, the AIs have consistently 
been shown to improve outcomes for postmenopausal women with hormone receptor-
positive breast cancer compared with tamoxifen.4 Each agent is taken on a daily basis for the 
duration of a minimum of 5 years, sometimes longer.
Despite the benefits of OET for BCS diagnosed with ER+ breast cancer, many BCS decide 
not to take their OET as recommended.7-9,13,17,30 The decision to take OET is not a single 
event decision, but a complex process that occurs over time as a series of one time daily 
decisions or twice daily decisions. Studies show that 30-50% of BCS who initiate therapy 
are not adherent to daily or twice-daily pill ingestion, and alarmingly 70% prematurely stop 
the therapy before the end of the once recommended 5-year period.2, 3 More recently, trials 
suggest that 10 years of tamoxifen are better than 5 years and that a program of extended 
adjuvant therapy of tamoxifen for 5 years followed by aromatase inhibitor for 5 years is 
effective for suitable candidates. 4This new recommendation causes more concern regarding 
the 70% early termination rates seen with a 5 year course of therapy.
Understanding a BCS's decisional supports (e.g. any support given to meet an identified 
decisional need) and decisional needs (e.g. any need a person may have that results in 
difficulty making a quality decision) is important to help facilitate adherence to OET, 
particularly when side effects are experienced.15 Tamoxifen side effects include hot flashes, 
weight gain, and loss of libido, and less commonly thromboembolic disease or endometrial 
pathologies.4-9 Aromatase inhibitor side effects include hot flashes, arthralgia, increased 
fractures, rash, and gastrointestinal upset.4, 5, 10-14 Understanding the decisional needs and 
support is a first step in creating a patient centered intervention to increase the percentage of 
BCS that correctly use this potentially life-saving treatment.
Purpose and Aims
The purpose of this review was to examine literature pertaining to OET non-adherence and 
side effects using the Ottawa Decision Support Framework categories of decisional supports 
and decisional needs as requisites for quality decision making. Aims were to use the 
available literature to (1) summarize the general nature of the studies, (2) summarize the link 
between prevalence of non-adherence and side effects, (3) summarize details of BCS's 
decisional supports, and (4) summarize thematic categories of BCS's unmet decisional 
needs.
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Conceptual Framework
The Ottawa Decision Support Framework was the conceptual framework for this study. The 
framework suggests that quality decisions result when decisional needs (e.g. knowledge, 
expectations, values) are understood and appropriate decisional supports (e.g. coaching, 
counseling, providing facts and probabilities) are provided.15 Decisional support is defined 
as any support that is given to meet an identified decisional need.15 The goal of decisional 
support is to address modifiable determinants of decision making that are suboptimal. These 
determinants can include inadequate knowledge, unrealistic expectations, unclear values, 
unclear norms, unwanted pressure, inadequate support, and inadequate personal and external 
resources to make the decision.4, 15, 16 Decisional needs are defined as any need a person 
may have that results in a difficulty to make a decision.15 Decisional needs are based on the 
knowledge, degree of certainty, expectations, and values one may have regarding the 
decision to be made.15, 16
Methods and Search Strategy
A systematic literature search was performed in PubMed and CINAHL. The PubMed 
database was selected because biomedical topics and the sciences are the primary foci of 
articles contained in this database, and these content areas directly related to the topic for 
this review. In addition, PubMed includes all articles indexed in MEDLINE.37 CINAHL was 
selected instead of OVID for its coverage of full-text nursing medical journals published by 
many different publishers. OVID searches are limited to articles published only by OVID 
and its publishing partners.38 Only peer reviewed articles were included in the review so 
PROQUEST or other dissertation search engines were not included. The search strategy for 
PubMED and CINAHL databases combined the search terms “aromatase inhibitors and 
adherence” and “tamoxifen and adherence.” In order to maximize inclusion, study type and 
publication date were not limited in the search strategy and articles including all factors 
associated with OET non-adherence (not just side effects as a single factor) were included. 
In addition, reference lists of identified review articles were hand searched to identify 
potentially relevant additional articles. First, titles and abstracts were screened. Second, the 
full texts of all potentially relevant articles were obtained and read to determine suitability 
for inclusion. Articles were identified for inclusion by the primary author according to 
predetermined criteria and then verified by a second reviewer.
Inclusion and exclusion criteria
To be eligible for this review, manuscripts had to meet the following inclusion criteria: (1) 
study population of adult females with a diagnosis of breast cancer, (2) intake of tamoxifen 
or aromatase inhibitors, (3) quantitative or qualitative analyses between medication and 
adherence (e.g. reported side effects attributed to non-adherence), and (4) full-length, 
original research. All types and stages of breast cancer were included. Excluded were 
articles that were (1) non-English language, (2) focused solely on reporting only adherence 
rates and not including factors contributing to non-adherence, (3) reviews, or (4) editorials, 
opinion papers, or abstracts.
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Data extraction
Data were extracted and organized into 4 separate tables and described below. All extracted 
data were verified by a second reviewer. Table 1 in analysis contained a general overview of 
the study characteristics including author, publication year, country where the study 
occurred, study design, length of study, cancer stage of participants, sample size, and the 
class of medication (tamoxifen or aromatase inhibitor). Table 2 focuses on rates of non-
adherence to the OET assessed in each study, the prevalence of side effects reported, and 
whether or not side effects were reported as a reason for non-adherence. Data extracted into 
Table 3 focused on decisional support participants reportedly received when receiving the 
OET prescription or at follow-up visits during recommended treatment. Using categories 
from the ODSF, the table delineates the type, source, timing, and content of provided 
support. Table 4 focuses on decisional needs. Identified needs are grouped according to four 
thematic categories that emerged from the available data within the articles: (1) regimen (not 
understanding timing, dose, or duration of OET), (2) beliefs about benefits and risks (OET 
being unhelpful, not necessary, or other negative or neutral beliefs about OET), (3) 
inadequate information (insufficient or confusing information, inadequate knowledge of side 
effects, or inadequate knowledge of tumor hormone status), and (4) no one to ask questions 
(inadequate support to gather information). For studies that contained no detailed 
information, decisional needs were marked as “not reported.”
Results
The search in the PubMed electronic database yielded 222 articles. After title and abstract 
screening, 99 articles were identified as potentially relevant. After removing 18 duplicates, 
81 full-text versions were screened in detail. Finally, 24 studies were included. The search in 
the CINAHL electronic database yielded 98 articles. After title and abstract screening, 24 
duplicate articles that were found in the PubMed were excluded and 6 articles were screened 
in detail. Finally, one additional article from the CINAHL search was included in the review. 
The manual search and reference check revealed no further relevant publications. The 
flowchart in the Figure 1 illustrates the selection process.
Characteristics of studies
The characteristics of identified studies are summarized in Table 1. Most articles were 
published after 2012 (n=13, 54.0%), 5, 6, 10-14, 17-22,36 with publication dates ranging from 
2001-2014. The majority of studies were conducted in the United States (n=12, 
48.0%),5-7, 9, 12-14, 21, 23-25 used quantitative methods, and reported on data collected using 
standardized self-report measures. Duration of study time points varied from a single one-
time mailing to 12 years, and not all studies reported this information. Stage of breast cancer 
ranged from 0-IV with not all studies reporting this information. Sample sizes ranged from 
30 BCS to 1,531 online posts by BCS. Participant ages ranged from 18 to >85. Class of OET 
studied was fairly well distributed across the relevant literature with 9 studies (36.0%) 
including both types of OET, 9 studies (37.5%) reporting on tamoxifen, and 7 studies 
(29.1%) reporting on aromatase inhibitors.
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Prevalence of non-adherence and side effects
Prevalence of non-adherence varied by drug. As shown in Table 2, non-adherence rates to 
tamoxifen ranged from around 7.3% to 54.0% and to AI ranged from 5.8% to 61.0%. In 
studies that reported non-adherence rates to overall therapy and not individually by drug 
adherence rates, rates were reported as 3.0%-58.0%.
Prevalence of side effects also varied by drug. As shown in Table 2, Tamoxifen side effect 
prevalence ranged from 8.0%-66.7% and AI side effect prevalence ranged from 
18.2%-66.7%. In studies that reported prevalence to overall therapy and not individually by 
drug, side effect prevalence rates ranged from 3.0%-69.8%. Four studies did not provide side 
effect prevalence rates but did include narrative description on the impact of experiencing 
side effects on adherence to OET.
Side effects were a reason for non-adherence in 23 of the 25 (92.0%) identified studies. 
Studies that focused on both tamoxifen and AIs often did not report side effects by drug. 
Four studies (16.0%) did not include information on specific side effects experienced. In 
addition, 1 study (4.2%) measured only severity and not type of side effects, 2 studies 
(8.3%) were specific to a single side effect, and 1 study (4.2%) reported the general 
experience of side effects. Hot flashes were described in 13 studies (54.2%), joint pains in 8 
studies (33.3%), fatigue/loss of energy in 7 studies (29.2%), mood problems in 6 studies 
(25.0%), sexual dysfunction in 5 studies (20.8%), night sweats in 4 studies (16.7%), and 
sleep problems in 2 studies (8.3%).
Decisional supports
Details on decisional support were absent in 13 (52.0%) of the identified studies, either 
because decisional support was not assessed or was not reported as part of the results. As 
shown in table 3, types and sources of decisional support included verbal information from 
providers as well as print or media (Internet, magazines, television, books). The time when 
decisional support was provided or sought by BCS was commonly reported as following 
initial prescription, but some articles also alluded to support being provided prior to initial 
prescription and also at follow-up visits. Message content was not always described within 
the articles. In 4 other studies (16.7%), information was limited to side effects only. In 
addition, in 4 studies (16.7%), participants specifically described the information they 
received as being insufficient. Only 1 study (4.2%) included information that BCS were 
informed of the importance of taking OET at almost every visit and had the opportunity to 
discuss side effects with their provider.
Decisional needs
Decisional needs are summarized in table 4. Decisional needs were not consistently assessed 
or reported, with 10 studies (40.0%) not reporting any information on decisional needs of 
BCS experiencing side effects from OET. In the remaining 15 studies (62.5%), the most 
common categories of decisional needs were inadequate information (n=7 studies) and belief 
of benefits and risks (n=6 studies). One study described anxiety and uncertainty in BCS 
regarding their symptom experience, especially when physicians could not explain the exact 
etiology of their symptoms.26 Another study included data about BCS not having anyone to 
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ask questions of and not understanding the duration, timing, or dose of their medication or 
having anyone available to answer questions.18
Discussion
In addition to providing a summary of the general nature of the studies that have been 
conducted on OET non-adherence in BCS who are experiencing side effects, there are 3 
main findings resulting from this review. First, the review summarizes evidence on the 
relationship between the experience of side effects and OET non-adherence. Second, this 
review demonstrates the absence of decisional supports provided or available to BCS who 
are experiencing OET side effects. Third, this review demonstrates BCS have unmet 
decisional needs in their OET side effect-related decision-making processes. Each of these 
findings is discussed in detail below.
Relationship of non-adherence and side effects
The relationship between OET non-adherence and side effects underscores the importance 
of this clinical problem and provide evidence supporting the widespread notion that OET 
side effects are a major reason for non-adherence. Reported non-adherence rates are thought 
to be dependent on a range of parameters, including whether the patients are participating in 
a clinical trial, the period since initiating treatment, and methods used to assess adherence 
and medication use.27 It is likely that rates of non-adherence varied within these studies for 
similar reasons. Regardless of rates, non-adherence was primarily attributed to the 
experience of side effects. Within this literature, women who reported experiencing OET 
side effects were two to four times more likely to discontinue OET earlier than five years,5-9 
and women who reported severe side effects were five times more likely to discontinue 
therapy earlier than five years.10 Though side effects caused women to switch to a different 
OET, switching does not prevent further side effects and many women subsequently 
discontinue even the second OET.11
Methods used to assess side effects of OET varied. Side effects were not assessed using 
comprehensive self-report measures, which interferes with understanding the true experience 
of the effect of these drugs. In addition, side effects were reported from overall OET, 
limiting our full understanding of side effects experienced by drug. Regardless, our review 
findings suggest that future research should be focused on improved understanding and 
elimination of non-adherence caused by side effects.
Absence of decisional supports
A second major finding of this review was the absence and inadequacy of available 
decisional supports for this population. The majority of current support was verbal direction 
from the provider occurring at the time of OET prescription. Details about existing support 
were limited, but when support was available, it was aimed mostly at the potential 
experience of side effects. Current support seemed to be lacking side effect management 
strategies or stressing the importance of remaining on a regimen even when experiencing 
side effects.
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Even when BCS reported receiving support, they reported it was inadequate. BCS reported 
they were not given understandable OET-related information. The information they did 
receive was not sufficient, and they did not have the opportunity to ask questions. Limiting 
support to information only and not considering additional determinants of decision making 
such as unrealistic expectations, unclear values, unclear norms, or inadequate personal and 
external resources increases the potential for poor quality decisions.16
The absence of decisional support may be partially due to the lack of decisional support 
tools for this population. Decisional support tools often come in the form of a decision aid, 
which is an intervention that helps patients make specific and deliberative choices among 
options. Decision aids often provide information on treatment options and outcomes relevant 
to a person's health status, and they include methods to clarify patients' values.28 The Patient 
Decision Aids Research Group, affiliated with the Ottawa Hospital Research Institute, is an 
international research team that designs and tests decision aids and decisional support 
training programs for patients and health practitioners. The group manages a database of 
decision aids that can be uploaded and shared if they adhere to established guidelines, 
including that they (1) meet the definition of a decision aid, (2) are not more than 5 years 
old, (3) provide references to scientific evidence used, and (4) are publicly available.15 
When the authors searched this database of decision aids that would support the OET 
decision-making process, only one tool was found. This decisional support tool is a decision 
aid for OET that focuses only on post-menopausal BCS making the initial decision to 
initiate therapy and does not take into consideration OET side effects or decision making as 
a process unfolding over time which can last 5-10 years.29 This further shows that there are 
inadequate resources for patients and providers to address the side effects and resulting 
impact on adherence of OET.
Unmet decisional needs
Importantly, this review showed that decisional needs are not systematically assessed in 
research or clinical practice. Assessment of decisional needs is important in decision making 
because it can identify what is important for the decision making, as well as what could be 
done better in the form of effective decisional support.15
A revealing finding from this review was the influence of beliefs about OET on adherence. 
BCS held complex beliefs about their OET, and for a number of BCS the decision to 
discontinue OET seemed to be the result of rational but misguided beliefs about their 
experience of side effects.30 Attempting to address their unmet decisional needs through 
seeking inaccurate information likely contributed to the formation of inaccurate beliefs 
about OET. This finding is important for adherence because it has been shown that BCS 
with negative or neutral beliefs about the value of OET were more likely to discontinue it.7 
BCS report having unmet needs regarding information they receive, and they report seeking 
additional information from sources other than their provider. BCS report having unmet 
needs regarding information they receive, and they report seeking additional information 
from sources other than their provider. Though BCS turn to alternative sources for OET-
related information, these sources may not provide adequate benefit due to uneven quality, 
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conflicting claims, redundancy, and difficulties associated with assessing information 
accuracy and applicability.31
Limitations
Review findings should be interpreted in light of some limitations. First, information on 
needs and support had to be extracted from methods and results sections. Thus, our findings 
may actually under-represent BCS's supports and needs, suggesting that a more detailed and 
purposeful study of supports and needs is warranted. A logical next step for research would 
be to conduct a detailed, basic, descriptive study of BCS's decision-making processes and 
the unfolding of their decisional needs and supports over time. Second, the literature search 
was limited to English language articles and a single comprehensive search engine. Search 
limitations could have limited the search results and potentially omitted additional findings 
published in other languages or identified in less popular journals not indexed within 
PubMed or CINAHL.
Conclusions
Overall, the prevalence of side effects was quite high and was cited as the major reason for 
discontinuing OET. Our study confirms that non-adherence to OET due to the experience of 
side effects remains an importance issue, primarily because BCS experiencing OET side 
effects have unmet decisional needs and lack adequate decisional supports.
This review indicates that more decisional support for BCS experiencing side effects related 
to OET may be needed. Although we know that side effects contribute to BCS's decisions to 
stop OET, we do not understand the process through which that occurs. In addition, although 
we know that BCS state they receive insufficient information about side effects from 
providers and seek out additional information, we do not fully understand that process or 
how it may relate to decision making. Future research is needed to further define the 
concepts of decisional needs and decisional supports for BCS experiencing side effects from 
OET in order to develop patient-centered materials to improve outcomes of OET therapy. 
Narrative accounts by BCS who are experiencing OET side effects will provide foundational 
descriptive information needed to generate interventions to improve quality decision 
making, such as a decision aid. In order to address the gap in currently available decision 
aids, next steps should include qualitative descriptive research to generate a full 
understanding of the decision-making process in BCS who experience OET side effects.
Implications for practice
This review generates some insights for providers who treat BCS with OETs, particularly 
when they are assessing OET adherence and side effects. The decision to take OET is not a 
single event decision, but a complex social process that occurs over time as a series of one 
time daily decisions or twice daily decisions over the course of up to 10 years. This decision 
making is further complicated for BCS who experience side effects. Categories of side 
effects, adherence, decisional support, and decisional needs are all associated with OET 
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decision making, and each of these categories is associated with specific clinical 
implications as discussed below.
At some point during OET treatment, a large proportion of BCS most likely experience 
some type of side effect. 5-7, 10-12, 17-20, 23-26, 30, 32-35 Inadequately managed side effects 
potentially increase non-adherence, leading to an increased risk of breast cancer 
recurrence.2,3 Current methods to assess side effects are inconsistent and unstandardized 
across the research literature.36 Existing literature suggests providers are failing to document 
the assessment of side effects. Furthermore, this review indicates that little is known about 
how information regarding side effects is communicated. Clinician recorded side effects tend 
to emphasize serious, life-threatening adverse events rather than patient-reported issues 
affecting quality of life. Information communicated to women by providers may not fully 
encompass the true side effect burden that may result from OET. Poor or inadequate 
communication fuels lack of understanding which can further negatively impact clinicians' 
abilities to support BCS in the management of their side effects and poor quality decisions 
made by BCS regarding their OET. We recommend that provider assessments include 
patient report of the experience of side effects from OET at every clinical visit as well as an 
assessment of adherence.
Decisional support for BCS can be provided in several different ways. Decisional support 
from providers may include health messages about the importance of continued OET or 
include a decisional support tool that addresses the problem (side effects from OET), 
alternatives, benefits, and risks related to deciding to take or not to take prescribed therapies. 
By providing decisional support to BCS using these methods, unmet decisional needs may 
be minimized, leading to a quality decision. Results of this review suggest the lack of 
decisional support for BCS lead to unmet decisional needs and provide a basis to guide 
health provider encounters with BCS taking OET.
According to the Ottawa Decision Support Framework, the primary driver of whether 
individuals are able to make quality decisions is whether their decisional needs are 
understood and supported.15 BCS who are inadequately informed about OET side effects or 
the importance of adherence are likely to have unmet decisional needs. By identifying unmet 
decisional needs, health providers can then be guided towards the types of patient centered 
OET health information BCS need in order to have adequate support. Providers can 
determine unmet decisional needs and tailor decisional support provided to BCS during 
patient encounters resulting in quality decisions that lead to side effect management 
ultimately resulting in improved adherence to OET.
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Figure 1. Flow Diagram
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Table 3
Decisional Support
Details Contained in Articles on the Type, Source, Timing, and Content of Messages Given for Decisional Support
Author(s) Type Source Timing Message Content
Aiello Bowles et al. * * * *
Atkins & Fallowfield * * * *
Bell et al. Verbal Provider Following RX *
Boonstra et al. Verbal Provider Prior to RX and 
at followup
Side effects information
Bramwell et al * * * *
Chim et al. * * * *
Cluz et al. Verbal Provider Following RX BCS reported they were not given 
understandable OET-related 
information BCS reported they did 
not consider their information 
sufficient BCS reported they did not 
have the opportunity to ask 
questions at diagnosis
Demissie et al. Print, media, verbal Books Magazines 
Television Provider
Following RX *
Fink et al. * * * *
Grunfield * * * *
Harrow, A. et al. Print, media, verbal Internet Provider Following RX Even though given side effects 
information, BCS reported not 
being asked whether or not they 
were still taking the medication at 
follow-up visits
Henry et al. * * * *
Kahn et al. Verbal Provider Following RX BCS reported not receiving 
information about side effects in 
advance from their provider BCS 
reported not receiving adequate 
information from their provider
Kemp * * * *
Kirk & Hudis, Verbal Provider Following RX 
and at follow-up 
visits
BCS told importance of taking 
OETs at almost every visit BCS 
discussed side effects with provider
Kyvernitakis et al. * * * *
Lash et al. * * * *
Mao et al. Media Internet message boards Not specified Side effects information
Oberguggenberger et al. * * * *
Owusu et al. * * * *
Pellegrini et al. Print, media, verbal Peers, Provider Internet Following RX Side effects information described 
OET as hormone or anti-hormone
Schover et al. Verbal Provider Following RX Side effects information
Simon et al. * * * *
Stanton, Petrie, & Partridge * * * *
Wouters et al. Verbal Provider Following RX Side effects information provided 
BCS reported they were not given 
information that taking OET at the 
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Details Contained in Articles on the Type, Source, Timing, and Content of Messages Given for Decisional Support
Author(s) Type Source Timing Message Content
same time every day was important 
BCS reported that the duration of 
therapy was unclear
Abbreviations: RX, Prescription;
*
no information available in article
Cancer Nurs. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Milata et al. Page 19
Ta
bl
e 
4
D
ec
isi
on
al
 N
ee
ds
Au
th
or
R
eg
im
en
 (t
im
ing
, d
os
e, 
du
ra
tio
n)
Be
lie
fs
 o
f B
en
ef
its
 &
 R
isk
s
In
ad
eq
ua
te
 In
fo
rm
a
tio
n
N
o 
O
ne
 to
 A
sk
 Q
ue
sti
on
s
N
o 
In
fo
rm
a
tio
n 
R
ep
or
te
d
A
ie
llo
 B
ow
le
s e
t a
l.
X
A
tk
in
s &
 F
al
lo
w
fie
ld
X
B
el
l e
t a
l.
X
B
oo
ns
tra
 e
t a
l.
X
B
ra
m
w
el
l e
t a
l
X
Ch
im
 e
t a
l.
X
Cl
uz
 e
t a
l.
D
em
iss
ie
 e
t a
l.
X
Fi
nk
 e
t a
l.
X
G
ru
nf
ie
ld
X
H
ar
ro
w
,
 
A
. e
t a
l.
X
H
en
ry
 e
t a
l.
X
K
ah
n 
et
 a
l.
X
K
em
p
X
K
irk
 &
 H
ud
is,
X
K
yv
er
n
ita
ki
s e
t a
l.
X
La
sh
 e
t a
l.
X
M
ao
 e
t a
l.
X
O
be
rg
ug
ge
nb
er
ge
r e
t a
l.
X
O
w
us
u 
et
 a
l.
X
Pe
lle
gr
in
i e
t a
l.
X
Sc
ho
v
er
 e
t a
l.
X
Si
m
on
 e
t a
l.
X
St
an
to
n,
 P
et
rie
, &
 P
ar
tr
id
ge
X
W
o
u
te
rs
 e
t a
l.
X
X
A
bb
re
v
ia
tio
ns
: X
 =
 a
rti
cl
e 
de
sc
rib
ed
 u
nm
et
 d
ec
isi
on
al
 n
ee
ds
 w
ith
in
 th
is 
ca
te
go
ry
Cancer Nurs. Author manuscript; available in PMC 2019 January 01.
